PX
Desconocido
NEWTBVAC: Discovery and preclinical development of new generation tuberculosis vaccines
PX'Therapeutics
participó en un
FP7:
With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An e...
Financiado
Financiado
EURONEUT-41: EUROpean consortium on NEUTralising antibodies using gp41
PX'Therapeutics
participó en un
FP7:
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, pept...
Financiado
Financiado
FIGHTMAL: Correlating protection against malaria with serum profiles against Plasmodium falciparum antigen rep...
PX'Therapeutics
participó en un
FP7:
People living in malaria endemic areas develop, with time, a form of immunity to infection and clinical disease mediated by antibodies direc...
Financiado
Financiado
FLUARRAY: Development and validation of a microarray based automated diagnostic system for the detection of in...
PX'Therapeutics
participó en un
FP7:
Influenza is an extremely contagious infection that is caused by distinct virus types and subtypes. Early diagnosis is crucial for disease t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.